Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer

The efficacy of CEA and CA15-3 tumor markers in monitoring breast cancer was evaluated in 1365 patients with either benign (n = 534) or malignant (n = 831) breast diseases. Thirty-nine breast cancer patients were monitored before and after neoadjuvant chemotherapy. Three hundred forty-nine patients...

Full description

Saved in:

Bibliographic Details
Published in:	Breast cancer research and treatment Vol. 68; no. 1; pp. 9 - 19
Main Authors:	DALESSANDRO, Roberta, ROSELLI, Mario, RICCIOTTI, Andrea, BOTTI, Claudio, CONTI, Francesca, VICI, Patrizia, CHIAPPETTA, Neva Rossi, COGNETTI, Francesco, BUONOMO, Oreste, GUADAGNI, Fiorella, FERRONI, Patrizia, MARIOTTI, Sabrina, SPILA, Antonella, ALOE, Simona, CARONE, Maria Daniela, ABBOLITO, Maria Rosaria, CARLINI, Sandro, PERRI, Pasquale
Format:	Journal Article
Language:	English
Published:	Dordrecht Springer 01-07-2001 Springer Nature B.V
Subjects:	Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Biomarkers, Tumor - blood Breast cancer Breast Neoplasms - blood Breast Neoplasms - diagnosis Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer research Cancer therapies Carcinoma, Ductal, Breast - blood Carcinoma, Ductal, Breast - diagnosis Carcinoma, Ductal, Breast - mortality Carcinoma, Ductal, Breast - secondary Carcinoma, Ductal, Breast - therapy Carcinoma, Lobular - blood Carcinoma, Lobular - diagnosis Carcinoma, Lobular - mortality Carcinoma, Lobular - secondary Carcinoma, Lobular - therapy Case-Control Studies Disease-Free Survival Female Fibrocystic Breast Disease - blood Gynecology. Andrology. Obstetrics Humans Italy Longitudinal Studies Mammary gland diseases Mastectomy Medical sciences Middle Aged Mucin-1 - blood Neoadjuvant Therapy Neoplasm Metastasis Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - therapy Neoplasm Staging Peptides - blood Postoperative Period Sensitivity and Specificity Tumors Italy Human Cytokeratin Tumor associated antigen Antigen CA 15 3 Tumoral marker Malignant tumor Neoadjuvant treatment Mammary gland diseases Chemotherapy Polypeptide Surgery Female Advanced stage Mammary gland Preoperative Benign neoplasm
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The efficacy of CEA and CA15-3 tumor markers in monitoring breast cancer was evaluated in 1365 patients with either benign (n = 534) or malignant (n = 831) breast diseases. Thirty-nine breast cancer patients were monitored before and after neoadjuvant chemotherapy. Three hundred forty-nine patients were monitored during post-surgical follow-up for either a minimum of 5 years or until time of recurrence. Twenty-one patients with metastases were also monitored during chemotherapy. Elevated CA 15-3 and TPS levels were found in 28.6% and 30.0% of patients. CA 15-3 and TPS sensitivities rose to 71.9% and 66.3% in metastatic patients, respectively. The addition of TPS to CA 15-3 increased the sensitivity up to 44.4% in the overall population, and to 87.6% in patients with metastases. During post-surgical follow-up CA 15-3 was elevated in 65.7% and TPS in 61.3% of patients with recurrence. The combination of TPS and CA 15-3 increased the overall sensitivity by 12.7%. Longitudinal monitoring of metastatic patients undergoing chemotherapy demonstrated that, when positive, both CA 15-3 and TPS paralleled response to treatment. TPS monitoring may provide additional value when used in combination with CA15-3 during post-surgical follow-up of breast cancer patients.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0167-6806 1573-7217
DOI:	10.1023/A:1017903724176